Search results
Showing 751 to 765 of 1961 results for nice guidelines
Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Evidence-based recommendations on roxadustat (Evrenzo) for treating symptomatic anaemia associated with chronic kidney disease in adults.
Canagliflozin in combination therapy for treating type 2 diabetes (TA315)
Evidence-based recommendations on canagliflozin (Invokana) in combination therapy for treating type 2 diabetes in adults.
Home Implementing NICE guidance...
Summaries of the best available evidence for selected medicines that are considered to be of significance to the NHS.
NICE has a key role in UK licensing and the evaluation of and access to new and innovative products for the health system.
Our Medical Technologies Evaluation Programme (MTEP) considers technologies that could offer benefits to patients and the health and social care system over current practice.
Supporting the health and care system to implement virtual wards
Virtual wards (also known as hospital at home) provide hospital level care at home.
Cardiovascular disease prevention: risk assessment (modifiable risk factors) (IND270)
This indicator covers the percentage of people aged 43 to 84 years with a modifiable risk factor who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
An approximate guide to the timings for the development of a piece of HealthTech guidance.
Tests in secondary care to identify people at high risk of ovarian cancer (HTG453)
Evidence-based recommendations on tests in secondary care to identify people at high risk of ovarian cancer. The tests are the IOTA ADNEX model, Overa (MIA2G), RMI I (at thresholds other than 250), ROMA and IOTA Simple Rules.
Engage at the optimal time for your technology appraisal, to achieve NICE guidance at the same time as marketing authorisation.
The NICE glossary provides brief definitions and explanations of terms used on the website. The terms describe how NICE works and how its guidance is produced.
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
Evidence-based recommendations on bronchial thermoplasty for severe asthma in adults. This involves applying heat to the inside walls of the airways.
View recommendations for HTG494Show all sections